Beyond Air (XAIR) Lytham Partners 2025 Investor Healthcare Summit summary

Technology and product overview

• Introduced a novel, FDA- and CE-marked nitric oxide delivery system that generates gas from ambient air, eliminating the need for cylinders and offering unlimited supply.

• System is approved for neonatal hypoxic respiratory failure in the US and peri/post-operative pulmonary hypertension in the EU.

• Second-generation device is smaller, designed for transport, and incorporates customer feedback for improved usability and safety.

• Over 1,850 patients treated in 60+ hospitals, with more than 130,000 hours of use and strong safety and efficacy data.

• Patents extend to 2044, covering both current and next-generation systems.

Market and competitive landscape

• US nitric oxide market is $350 million, global market $700 million, with significant growth potential, especially ex-US.

• Competitors rely on cylinder or cassette-based systems, which are logistically challenging and less efficient.

• Company’s system offers faster treatment initiation, no hazardous storage, and predictable maintenance.

• Cassette-based competitor has >10% market share, indicating strong demand for alternatives to cylinders.

• Anticipates market share gains if cardiac surgery indication is approved by FDA.

Commercialization and partnerships

• Revenue model is fee-for-service with contracts ranging from one to four years.

• Partnership with Getz Healthcare covers 10 Southeast Asian countries, with product shipments expected soon.

• Additional international partnerships anticipated within 24 months, aiming for global presence by fiscal 2027.

• CE Mark triggered a $1 million milestone payment and accelerated regulatory approvals in partner countries.

• Upgraded system launched in the US in spring 2023, receiving positive feedback.